NEJM – pulmonary and critical care
- Physiological Basis of Formulas Estimating Central Systolic Pressure
- The authors reply
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
JAMA – critical care
- “ Is There a Doctor on the Ship?”
- Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia Research Summary
- Sacred Spaces
- Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia
- A Multinational Trial of Rapid Antimicrobial Susceptibility Testing
- Remote Multicomponent Rehabilitation in Intensive Care Unit Survivors Research Summary
- The Future of Survivorship in Critical Illness
- Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications
- Remote Multicomponent Rehabilitation in Intensive Care Unit Survivors
- Symptom-Based Dosing for Neonatal Opioid Withdrawal
Lancet and critical care (via Pubmed)
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
Chest – critical care
- Analgosedation practices and the impact of sedation depth on clinical outcomes among patients requiring mechanical ventilation in the emergency department: a cohort study
- ECMO for Adult Respiratory Failure: 2017 Update
- Investing in New Technology in Pulmonary Medicine– Navigating the Tortuous Path to Success
- Rebuttal From Drs Truog and Tasker
- Counterpoint: “Should informed consent be required for apnea testing in patients with suspected brain death?" Yes
- Improved Early Detection of Sepsis in the Emergency Department with a Novel Monocyte Distribution Width Biomarker
- Video Laryngoscopy for Endotracheal Intubation of Critically Ill Adults: A Systemic Review and Meta-analysis
- Rebuttal From Dr Powell
- Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent Risk Factor for Mortality in Patients With Bronchiectasis A Multicenter Cohort Study
- An Elderly Man With Pancreatic Neuroendocrine Tumor and a Cavitary Right Upper Lobe Lung Mass
- A 58-Year-Old Man With Fatigue, Weight Loss, and Diffuse Miliary Pulmonary Opacities
- Giants in Chest Medicine Karlman Wasserman, MD, PhD, FCCP
- Obstructive Sleep Apnea and Diabetes: A State-of-the-Art Review
- Intensive Monitoring of Urine Output is Associated with Increased Detection of Acute Kidney Injury and Improved Outcomes
- Decision-making on withholding or withdrawing life-support in the ICU: A worldwide perspective
Critical Care Medicine
- The authors reply
- Physiological Basis of Formulas Estimating Central Systolic Pressure
- The Virtue of Conditional Care in End-of-Life Decision-Making
- The authors reply:
- Middle-Latency Evoked Potentials and Quantitative Electroencephalogram: Valuable Complements in the Prognostication of Disorders of Consciousness
- Interpreting Hyperoxemia in Venoarterial Extracorporeal Membrane Oxygenation Patients
- The authors reply:
- The Weight of the Situation: The Case for Standardizing Vasopressor Dosing Units
- Progress, Not Just Predictions
- Deceased Organ Donation in Japan: Lessons, Leadership, and Challenges to Change Culture
- In Their Own Words: Understanding Families’ Experience With Death as Part of Controlled Donation After Circulatory Determination of Death
- Defining the Resolution of Acute Respiratory Distress Syndrome: A Missing Piece in Critical Care
- When Strategy Meets Reality: Temperature Management After In-Hospital Cardiac Arrest
- Disparities in Finding Delirium in Critically Ill Latinos
- Trends in Use of IV Vitamin C Among Patients With Sepsis: Erratum
AJRCCM
- VEGF-based Therapy for Congenital Diaphragmatic Hernia: A Breakthrough or a Hidden Risk?
- Environmental Sustainability in Intensive Care: From Awareness to Action
- From Web to Collapse: Small Airway Disease Trajectory in Chronic Obstructive Pulmonary Disease
- Reply to Sun et al.: Neuromuscular Blockade Efficacy in High Elastance Acute Respiratory Distress Syndrome: Signal or Statistical Noise?
- On Not Betraying Our Trainees, Especially Now
- Moving from Critical Illness Syndromes toward Biologic Molecular Endotypes: Making Progress
- Think Locally, Act Globally: Resolving the Peripheral Immune Milieu in Bacterial Pneumonia
- Can a Spark Light an Eternal Flame? Lessons from Physical Activity Coaching in Chronic Obstructive Pulmonary Disease
- Reply to Zhou et al.: Methodological Pitfalls Undermine Industrial Emission-related Lung Cancer Risk Assessment
- The Mirage of Individualized Therapy in the United States: Barriers in Pulmonary Hypertension Due to Sickle Cell Disease and Sarcoidosis
- Bronchial Expansion after Lung Recruitment and Personalized Positive End-Expiratory Pressure in an Obese ICU Patient with Pneumonia
- Perivascular Dynamics, Sleep Apnea, and Memory: Interpreting a Moving Target
- Neuromuscular Blockade Efficacy in High Elastance Acute Respiratory Distress Syndrome: Signal or Statistical Noise?
- Diaphragmatic Flutter Causing Patient–Ventilator Dyssynchrony
- Reply to Zeng: VEGF-based Therapy for Congenital Diaphragmatic Hernia: A Breakthrough or a Hidden Risk?
ICM – from ESICM